Role of brain iron accumulation in cognitive dysfunction: Evidence from animal models and human studies

Journal of Alzheimer's Disease

Volumn 34, Issue 4, 2013, Pages 797-812

  Schröder, Nadja ^a,b   Figueiredo, Luciana Silva ^a   De Lima, Maria Noêmia Martins ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

cognitive manifestations; Iron; memory; neonatal; neurodegenerative disorders

Indexed keywords

BUTYRIC ACID; CANNABIDIOL; DEFEROXAMINE; GALANTAMINE; IRON; OXOTREMORINE; ROLIPRAM; ROSUVASTATIN; SELEGILINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

APOPTOSIS; BRAIN LEVEL; BRAIN METABOLISM; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; COGNITION; COGNITIVE DEFECT; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IRON CHELATION; IRON OVERLOAD; MACROGLIA; MAZE TEST; MEMORY CONSOLIDATION; MEMORY DISORDER; MENTAL PERFORMANCE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 84876361328     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121996     Document Type: Review

References (130)

1. Connor JR, Pavlick G, Karli D, Menzies SL, Palmer C (1995) A histochemical study of iron-positive cells in the developing rat brain. J Comp Neurol 355, 111-123.
2. Sian-Hülsmann J, Mandel S,Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 118, 939-957.
3. LozoffB(2011) Early iron deficiency has brain and behavior effects consistent with dopaminergic dysfunction. J Nutr 141, 740S-746S.
4. Fretham SJ, Carlson ES, Georgieff MK (2011) The role of iron in learning and memory. Adv Nutr 2, 112-121.
5. Papanikolaou G, PantopoulosK(2005) Iron metabolism and toxicity. Toxicol Appl Pharmacol 202, 199-211. (Pubitemid 40040559)
6. Gaasch JA, Lockman PR, Geldenhuys WJ, Allen DD, Van der Schyf CJ (2007) Brain iron toxicity: Differential responses of astrocytes, neurons, and endothelial cells. Neurochem Res 32, 1196-1208. (Pubitemid 46817469)
7. Dexter DT, Wells FR, Agid F, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in postmortem Parkinsonian brain. Lancet 2, 1219-1220. (Pubitemid 17156630)
8. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
9. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52, 515-520. (Pubitemid 19037617)
10. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56, 978-982. (Pubitemid 21922711)
11. Hirsch EC, Brandel J-P, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An X-ray microanalysis. J Neurochem 56, 446-451. (Pubitemid 21901982)
12. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Masliah E (1999) Oxidative stress induces amyloid-like aggregate formation on NACP/alpha-synuclein in vitro. Neuroreport 10, 717-721. (Pubitemid 29393812)
13. Paik SR, Shin HJ, Lee JH, Chang CS, Kim J (1999) Cooper(II)-induced self- oligomerization of alphasynuclein. Biochem J 340, 821-828.
14. Zecca L,YoudimMBH,Riederer P, Connor JR, CrichtonRR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5, 863-873. (Pubitemid 39482155)
15. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1994) Increased nigral iron content and alteration in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52, 1830-1836. (Pubitemid 19140770)
16. Good PF, Perl DP, Bierer LM, Schmeidler J (1992) Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study. Ann Neurol 31, 286-292.
17. Connor JR, Menzies SL, St Martin SM, Mufson EJ (1992) A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 31, 75-78.
18. Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA (2002) Iron: A pathological mediator of Alzheimer disease? Dev Neurosci 24, 184-187. (Pubitemid 36151449)
19. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52. (Pubitemid 28277534)
20. Barnham KJ, Haeffner GD, Ciccotosto GD, Curtain CC, TewD,Mavros C, Beyreuther K, Carrington D, Masters CL, Cherny RA, Cappai R, Bush AI (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J 18, 1427-1429. (Pubitemid 39561603)
21. Schubert D, ChevionM(1995) The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun 216, 702-707.
22. Huang X, Atwood CS, Hartshorm MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609-7616. (Pubitemid 29289332)
23. Squitti R (2012) Metals in Alzheimer's disease: A systemic perspective. Front Biosci 17, 451-472.
24. Batista-Nascimento L, Pimentel C, Menezes RA, Rodrigues-Pousada C (2012) Iron and neurodegeneration: From cellular homeostasis to disease. Oxid Med Cell Longev 2012, 128647.
25. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR (2002) An iron-responsive element type II in the 5′- untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277, 45518-45528. (Pubitemid 36159162)
26. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E,Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI (2010) Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142, 857-867.
27. Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D (2009) Heme oxygenase-1 and neurodegeneration: Expanding frontiers of engagement. J Neurochem 110, 469-485.
28. Schipper HM (2012) Neurodegeneration with brain iron accumulation - clinical syndromes and neuroimaging. Biochim Biophys Acta 1822, 350-360.
29. Freeman K, Gregory A, Turner A, Blasco P, Hogarth P, Hayflick S (2007) Intellectual and adaptive behaviour functioning in pantothenate kinase-associated neurodegeneration. J Intellect Disabil Res 51, 417-426. (Pubitemid 46746070)
30. Paisán-Ruiz C, Guevara R, FederoffM, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houlden H (2010) Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 25, 1791-1800.
31. Lehn A, Boyle R, Brown H, Airey C, MellickG(2012) Neuroferritinopathy. Parkinsonism Relat Disord 18, 909-915.
32. Rech RL, De Lima MN, Dornelles A, Garcia VA, Alcalde LZ, Vedana G, Schröder N (2010) Reversal of ageassociated memory impairment by rosuvastatin in rats. Exp Gerontol 45, 351-356.
33. Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY (2013) Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 34, 562-575.
34. Railey AM, Groeber CM, Flinn JM (2011) The effect of metals on spatial memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 24, 375-381.
35. Lozoff B, Castillo M, Clark KM, Smith JB (2012) Iron-fortified vs low-iron infant formula: Developmental outcome at 10 years. Arch Pediatr Adolesc Med 166, 208-215.
36. Taylor EM, Morgan EH (1990) Developmental changes in transferrin and iron uptake by the brain in the rat. Brain Res Dev Brain Res 55, 35-42. (Pubitemid 20241301)
37. Dwork AJ, Lawler G, Zybert PA, Durkin M, Osman M, Willson N, Barkai AI (1990) An autoradiographic study of the uptake and distribution of iron by the brain of the young rat. Brain Res 518, 31-39. (Pubitemid 20197027)
38. Fredriksson A, Schröder N, Eriksson P, Izquierdo I, Archer T (1999) Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol App Pharmacol 159, 25-30. (Pubitemid 29404758)
39. Fredriksson A, Schröder N, Eriksson P, Izquierdo I, Archer T (2000) Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period. Brain Res Dev Brain Res 119, 65-74. (Pubitemid 30058383)
40. Schröder N, Fredriksson A, Vianna M, Roesler R, Izquierdo I, Archer T (2001) Memory deficits in adult rats following postnatal iron administration. Behav Brain Res 124, 77-85. (Pubitemid 32567561)
41. Maaroufi K, Ammari M, Jeljeli M, Roy V, Sakly M, Abdelmelek H (2009) Impairment of emotional behavior and spatial learning in adult Wistar rats by ferrous sulfate. Physiol Behav 96, 343-349.
42. De Lima MN, Polydoro M, Laranja DC, Bonatto F, Bromberg E, Moreira JC, Dal-Pizzol F, Schröder N (2005) Recognition memory impairment and brain oxidative stress induced by postnatal iron administration. Eur J Neurosci 21, 2521-2528. (Pubitemid 40813933)
43. De Lima MN, Laranja DC, Caldana F, Bromberg E, Roesler R, Schröder N (2005) Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. Exp Gerontol 40, 506-511. (Pubitemid 40884503)
44. De Lima MN, Dias CP, Presti-Torres J, Dornelles A, Garcia VA, Scalco F, Guimarães MR, Petry RC, Bromberg E, Constantino L, Budni P, Dal-Pizzol F, Schröder N (2008) Reversion of age-related recognition memory impairment by iron chelation in rats. Neurobiol Aging 29, 1052-1059. (Pubitemid 351697994)
45. De Lima MN, Presti-Torres J, Garcia VA, Guimarães MR, Scalco FS, Roesler R, Schröder N (2008) Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats. Neuropharmacology 55, 788-792.
46. Squire LR (2004) Memory systems of the brain: A brief history and current perspective. Neurobiol Learn Mem 82, 171-177. (Pubitemid 39298714)
47. Squire LR, Wixted JT, Clark RE (2007) Recognition memory and the medial temporal lobe: A new perspective. Nat Rev Neurosci 8, 872-883. (Pubitemid 350006215)
48. Packard MG, Knowlton BJ (2002) Learning and memory functions of the Basal Ganglia. Annu Rev Neurosci 25, 563-593. (Pubitemid 34748029)
49. De Lima MN, Laranja DC, Caldana F, Grazziotin MM, Garcia VA, Dal-Pizzol F, Bromberg E, Schröder N (2005) Selegiline protects against recognition memory impairment induced by neonatal iron treatment. Exp Neurol 196, 177-183. (Pubitemid 41416659)
50. De Mello N, Souza-Junior IQ, Carobrez AP (2005) Pilocarpine prevents age-related spatial learning impairments in rats. Behav Brain Res 158, 263-268. (Pubitemid 40208472)
51. Iyo M, Namba H, Fukuski K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T (1997) Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349, 1805-1809. (Pubitemid 27258658)
52. Bohnen NI, Kaufer DI, Hendrickson R, Ivance L, Lopresti B, Davis J, Constantine G, Mathis C, Moore R, DeKosky S (2005) Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 380, 127-132. (Pubitemid 40602342)
53. Perez VP,De Lima MN, Da Silva RS, Dornelles AS,Vedana G, Bogo MR, Bonan CD, Schröder N (2010) Iron leads to memory impairment that is associated with a decrease in acetylcholinesterase pathways. Curr Neurovasc Res 10, 1567-2026.
54. Abel T, Nguyen PV, Barad M, Deuel TA, Kandel ER, Bourtchouladze R (1997) Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell 88, 615-626. (Pubitemid 27152404)
55. Bevilaqua L, Ardenghi P, Schröder N, Bromberg E, Schmitz PK, Schaeffer E, Quevedo J, Bianchin M, Walz R, Medina JH, Izquierdo I (1997) Drugs acting upon the cyclic adenosine monophosphate/protein kinase A signaling pathway modulate memory consolidation when given late after training into rat hippocampus but not amygdala. Behav Pharmacol 8, 331-338. (Pubitemid 27402100)
56. Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I,Hawkins RD, KandelER(1999) Age-related defects in spatial memory are correlated with defects in the late phase of hipocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A 96, 5280-5285. (Pubitemid 29214574)
57. Schafe GE, Nadel NV, Sullivan GM, Harris A, LeDoux JE (1999) Memory consolidation for contextual and auditory fear conditioning is dependent on protein synthesis, PKA, and MAP kinase. Learn Mem 6, 97-110. (Pubitemid 29207259)
58. Quevedo J, Vianna MR, Martins MR, Barichello T, Medina JH, Roesler R, Izquierdo I (2004) Protein synthesis, PKA, and MAP kinase are differentially involved in short- and long-term memory in rats. Behav Brain Res 154, 339-343. (Pubitemid 39093984)
59. ArnstenAF, RamosBP, Birnbaum SG,Taylor JR (2005) Protein kinase A as a therapeutic target for memory disorders: Rationale and challenges. Trends Mol Med 11, 121-128. (Pubitemid 40348989)
60. Middleton LE, Yaffe K (2009) Promising strategies for the prevention of dementia. Arch Neurol 66, 1210-1215.
61. Cassol-Jr OJ, Comim CM, Silva BR, Hermani FV, Constantino LS, Felisberto F, Petronilho F, Hallak JE, De Martinis BS, ZuardiAW, Crippa JA, Quevedo J, Dal-Pizzol F (2010) Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res 1348, 128-138.
62. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on betaamyloid- induced toxicity in PC12 cells. J Neurochem 89, 134-141. (Pubitemid 38420682)
63. Fagherazzi EV, Garcia VA, Maurmann N, Bervanger T, Halmenschlager LH, Busato SB, Hallak JE, Zuardi AW, Crippa JA, Schröder N (2012) Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology (Berl) 219, 1133-1140.
64. Barrett RM, Wood MA (2008) Beyond transcription factors: The role of chromatin modifying enzymes in regulating transcription required for memory. Learn Mem 15, 460-467. (Pubitemid 352008668)
65. Mikaelsson MA, Miller CA (2011) The path to epigenetic treatment of memory disorders. Neurobiol Learn Mem 96, 13-18.
66. Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC, Cota P, Wittnam JL, Gogol-Doering A, Opitz L, Salinas-Riester G, Dettenhofer M, Kang H, Farinelli L, Chen W, Fischer A (2010) Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328, 753-756.
67. Da Silva PF, Garcia VA, Dornelles AS, Da Silva VK, Maurmann N, Portal BCD, Ferreira RDP, Piazza FC, Roesler R, Schröder N (2012) Memory impairment induced by brain iron overload is accompanied by reduced H3K9 acetylation and ameliorated by sodium butyrate. Neuroscience 200, 42-49.
68. Long DA, Ghosh K, Moore AN, Dixon CE, Dash PK (1996) Deferoxamine improves spatial memory performance following experimental brain injury in rats. Brain Res 717, 109-117. (Pubitemid 26153442)
69. De Lima MN, Presti-Torres J, Caldana F, Grazziotin MM, Scalco F, GuimarãesMR,BrombergE, Franke SI, Henriques JA, Schröder N (2007) Desferoxamine reverses neonatal iron-induced recognition memory impairment in rats. Eur J Pharmacol 570, 111-114. (Pubitemid 47247692)
70. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O (2012) Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech Ageing Dev 133, 267-274.
71. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O (2012) The novel multi-target iron chelating-radical scavenging compound m30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid Redox Signal 17, 860-877.
72. Fine JM, Baillargeon AM, Renner DB, Hoerster NS, Tokarev J, Colton S, Pelleg A, Andrews A, Sparley KA, Krogh KM, Frey WH, Hanson LR (2012) Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice. Exp Brain Res 219, 381-390.
73. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308.
74. Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI (2007) Selective iron chelation in Friedreich ataxia: Biologic and clinical implications. Blood 110, 401-408. (Pubitemid 47026862)
75. Whitfield JB, Treloar S, Zhu G, Powell LW, Martin NG (2003) Relative importance of female-specific and nonfemale- specific effects on variation in iron stores between women. Br J Haematol 120, 860-866. (Pubitemid 36315112)
76. Bartzokis G, Tishler TA, Lu PH, Villablanca P, Altshuler LL, Carter M, Huang D, Edwards N, Mintz J (2007) Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 28, 414-423. (Pubitemid 46177391)
77. Hahn P, Song Y, Ying GS, He X, Beard J, Dunaief JL (2009) Age-dependent and gender-specific changes in mouse tissue iron by strain. Exp Gerontol 44, 594-600.
78. Thulluri S, Wu M, Blough ER, Manne ND, Litchfield AB, Wang B (2012) Regulation of iron-related molecules in the rat hippocampus: Sex- and age-associated differences. Ann Clin Lab Sci 42, 145-151.
79. Bartzokis G, Lu PH, Tishler TA, Peters DG, Kosenko A, Barrall KA, Finn JP, Villablanca P, Laub G, Altshuler LL, Geschwind DH, Mintz J, Neely E, Connor JR (2010) Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J Alzheimers Dis 20, 333-341.
80. Connor JR, Lee SY (2006) HFE mutations and Alzheimer's disease. J Alzheimers Dis 10, 267-276. (Pubitemid 44763997)
81. Lehmann DJ, Schuur M, Warden DR, Hammond N, Belbin O, Kölsch H, Lehmann MG,Wilcock GK, Brown K, Kehoe PG, Morris CM, Barker R, Coto E, Alvarez V, Deloukas P, Mateo I, Gwilliam R, Combarros O, Arias-Vásquez A, Aulchenko YS, Ikram MA, Breteler MM, van Duijn CM, Oulhaj A, Heun R, Cortina-Borja M, Morgan K, Robson K, Smith AD (2012) Transferrin and HFE genes interact in Alzheimer's disease risk: The Epistasis Project. Neurobiol Aging 33, 202.e1-13.
82. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al- Chalabi A, ShawCE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N,Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
83. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, Nalls MA, Chen K, LeeW, Chewning K, Villa SE, Meechoovet HB, Gerber JD, Frost D, Benson HL, O'Reilly S, Chibnik LB, Shulman JM, Singleton AB, Craig DW, Van Keuren-Jensen KR, Dunckley T, Bennett DA, De Jager PL, Heward C, Hardy J, Reiman EM, Huentelman MJ (2010) Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 19, 3295-3301.
84. Scotland PB, Heath JL, Conway AE, Porter NB, Armstrong MB,Walker JA, Klebig ML, Lavau CP,Wechsler DS (2012) The PICALM protein plays a key role in iron homeostasis and cell proliferation. PLoS One 7, e44252.
85. Ding B, Chen KM, LingHW, Sun F, Li X,Wan T, Chai WM, Zhang H, Zhan Y, Guan YJ (2009) Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J Magn Reson Imaging 29, 793-798.
86. Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E (2012) MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 59, 2625-2635.
87. Pfefferbaum A, Adalsteinsson E, Rohlfing T, Sullivan EV (2009) MRI estimates of brain iron concentration in normal aging: Comparison of field-dependent (FDRI) and phase (SWI) methods. Neuroimage 47, 493-500.
88. Hallgren B, Sourander P (1958) The effect of age on the non-haemin iron in the human brain. J Neurochem 3, 41-51.
89. Yan SQ, Sun JZ,Yan YQ,Wang H, LouM(2012) Evaluation of brain iron content based on magnetic resonance imaging (MRI): Comparison among phase value, R2* and magnitude signal intensity. PLoS One 7, e31748.
90. Hare DJ, Gerlach M, Riederer P (2012) Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients. J Neural Transm 119, 1515-1521.
91. Pujol J, Junqué C, Vendrell P, Grau JM, Martí-Vilalta JL, Olivé C, Gili J (1992) Biological significance of iron-related magnetic resonance imaging changes in the brain. Arch Neurol 49, 711-717.
92. House MJ, St Pierre TG, Foster JK, Martins RN, Clarnette R (2006) Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. AJNRAmJ Neuroradiol 27, 430-439. (Pubitemid 44897857)
93. Brass SD, Benedict RH, Weinstock-Guttman B, Munschauer F, Bakshi R (2006) Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 12, 437-444. (Pubitemid 44132584)
94. Sullivan EV, Adalsteinsson E, Rohlfing T, Pfefferbaum A (2009) Relevance of iron deposition in deep gray matter brain structures to cognitive and motor performance in healthy elderlymenandwomen: Exploratory findings. Brain Imaging Behav 3, 167-175.
95. Bartzokis G, Lu PH, Tingus K, Peters DG, Amar CP, Tishler TA, Finn JP, Villablanca P, Altshuler LL, Mintz J, Neely E, Connor JR (2011) Gender and iron genes may modify associations between brain iron and memory in healthy aging. Neuropsychopharmacology 36, 1375-1384.
96. Rodrigue KM, Daugherty AM, Haacke EM, Raz N (2012) The role of hippocampal iron concentration and hippocampal volume in age-related differences in memory. Cereb Cortex, in press.
97. Zhu WZ, Zhong WD, Wang W, Zhan CJ, Wang CY, Qi JP, Wang JZ, Lei T (2009) Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. Radiology 253, 497-504.
98. Penke L, Valdés Hernandéz MC, Maniega SM, Gow AJ, Murray C, Starr JM, Bastin ME, Deary IJ, Wardlaw JM (2012) Brain iron deposits are associated with general cognitive ability and cognitive aging. Neurobiol Aging 33, 510-517.
99. SmithMA,Zhu X, Tabaton M, Liu G,McKeelDWJr, Cohen ML,Wang X, Siedlak SL, Dwyer BE, Hayashi T, Nakamura M, Nunomura A, Perry G (2010) Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 19, 363-372.
100. Umur EE, Oktenli C, Celik S, Tangi F, Sayan O, Sanisoglu YS, Ipcioglu O, Terekeci HM, Top C, Nalbant S, Kucukardali Y (2011) Increased iron and oxidative stress are separately related to cognitive decline in elderly. Geriatr Gerontol Int 11, 504-509.
101. Milward EA, Bruce DG, Knuiman MW, Divitini ML, Cole M, Inderjeeth CA, Clarnette RM, Maier G, Jablensky A, Olynyk JK (2010) A cross-sectional community study of serum iron measures and cognitive status in older adults. J Alzheimers Dis 20, 617-623.
102. Berg D, Gerlach M, Youdim MBH, Double KL, Zecca L, Riederer P, Becker G (2001) Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 79, 225-236. (Pubitemid 32988938)
103. Belkacemi A, Ramassamy C (2012) Time sequence of oxidative stress in the brain from transgenic mouse models of Alzheimer's disease related to the amyloid-β cascade. Free Radic Biol Med 52, 593-600.
104. Deibel MA, Ehmann WD, Markesbery WR (1996) Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress. J Neurol Sci 143, 137-142. (Pubitemid 26402800)
105. Dal-Pizzol F, Klamt F, Frota ML, Andrades ME, Caregnato FF,Vianna M, Schröder N, Quevedo J, Izquierdo I, Archer T, Moreira JC (2001) Neonatal iron exposure induces oxidative stress in adult wistar rat. Brain Res Dev Brain Res 130, 109-114. (Pubitemid 32830978)
106. Budni P, De Lima MN, Polydoro M, Moreira JC, Schröder N, Dal-Pizzol F (2007) Antioxidant effects of selegiline in oxidative stress induced by iron neonatal treatment in rats. Neurochem Res 32, 965-972. (Pubitemid 46726015)
107. Rodriguez JJ, Olabarria M, Cchvatal A, Verkhratsky A (2009) Astroglia in dementia and Alzheimer's disease. Cell Death Diff 16, 378-385.
108. Wharton SB, O'Callaghan JP, Savva GM, Nicoll JA, Matthews F, Simpson JE, Forster G, Shaw PJ, Brayne C, Ince PG (2009) MRC cognitive function and ageing neuropathology study group. Population variation in glial fibrillary acidic protein levels in brain ageing: Relationship to Alzheimer-type pathology and dementia. Dement Geriatr Cogn Disord 27, 465-473.
109. Manaye KF, Wang PC, O'Neil JN, Huang SY, Xu T, Lei DL, Tizabi Y, Ottinger MA, Ingram DK, Mouton PR (2007) Neuropathological quantification of dtg APP/PS1: Neuroimaging, stereology, and biochemistry. Age 29, 87-96. (Pubitemid 350112202)
110. Fernandez LL, Carmona M, Portero-Otin M, Naudi A, Pamplona R, Schröder N, Ferrer I (2010) Effects of increased iron intake during the neonatal period on the brain of adult AβPP/PS1 transgenic mice. J Alzheimers Dis 19, 1069-1080.
111. Fernandez LL, De Lima MN, Scalco F, Vedana G, Miwa C, Hilbig A, Vianna M, Schröder N (2011) Early post-natal iron administration induces astroglial response in the brain of adult and aged rats. Neurotox Res 20, 193-199.
112. Morrison JH, Hof PR (1997) Life and death of neurons in the aging brain. Science 278, 412-419. (Pubitemid 27454417)
113. Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1, 120-129.
114. Stefanis L (2005) Caspase-dependent and -independent neuronal death: Two distinct pathways to neuronal injury. Neuroscientist 11, 50-62. (Pubitemid 40223090)
115. Polla AS, Polla LL, Polla BS (2003) Iron as the malignant spirit in successful ageing. Ageing Res Rev 2, 25-37. (Pubitemid 37443916)
116. Miwa CP, De Lima MN, Scalco F, Vedana G, Mattos R, Fernandez LL, Hilbig A, Schröder N, Vianna M (2011) Neonatal iron treatment increases apoptotic markers in hippocampal and cortical areas of adult rats. Neurotox Res 19, 527-535.
117. Lovell MA, Markesbery WR (2006) Amyloid beta peptide, 4-hydroxynonenal and apoptosis. Curr Alzheimer Res 3, 359-364. (Pubitemid 44351479)
118. Kell DB (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84, 825-889.
119. Zhang S, Wang J, Song N, Xie J, Jiang H (2009) Upregulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol Aging 30, 1466-1476.
120. Zabel C, Nguyen HP, Hin SC, Hartl D, Mao L, Klose J (2010) Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders. J Proteomics 73, 2230-2238.
121. Fioravante D, Byrne JH (2011) Protein degradation and memory formation. Brain Res Bull 85, 14-20.
122. van Tijn P, Hobo B, Verhage MC, Oitzl MS, van Leeuwen FW, Fischer DF (2011) Alzheimer-associated mutant ubiquitin impairs spatial reference memory. Physiol Behav 102, 193-200.
123. Klyubin I, Cullen WK, Hu NW, Rowan MJ (2012) Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brai 5, 25.
124. Zündorf G, Reiser G (2011) Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection. Antioxid Redox Signal 14, 1275-1288.
125. Hardingham GE (2009) Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 37, 1147-1160.
126. Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 15, 349-357.
127. Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10, 209-219.
128. Portela A, Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol 28, 1057-1068.
129. Hu NW, Ondrejcak T, Rowan MJ (2012) Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances. Pharmacol Biochem Behav 100, 855-862.
130. Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221, 555-563.